DFDA

Nirmatrelvir/Ritonavir (Paxlovid)

Treatment for Long Covid

Typical Dosage: 300mg nirmatrelvir / 100mg ritonavir twice daily for 5 days

Effectiveness
50%
Safety Score
65%
Clinical Trials
9
Participants
7.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
300mg nirmatrelvir / 100mg ritonavir twice daily for 5 days
Time to Effect
Days (acute prevention), weeks to months (existing Long COVID)
Treatment Duration
5 days (acute), potentially longer if used off-label for Long COVID
Evidence Quality
MODERATE
Confidence Score
60%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$530
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$680
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$1,700
Prescription Access Economics
Annual Societal Loss per Patient
$160
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$125/year
Time Cost
$25/year
Travel + wait time
Insurance Admin Cost
$10/year
Prior auth, claims
Rx Price
$530/year
Potential OTC Price
$150/year
Estimated if OTC available
Early Treatment Benefit
+0.08 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
MODERATE
Missed Diagnosis Risk
LOW
Nirmatrelvir/Ritonavir (Paxlovid) Outcomes

for Long Covid

Efficacy Outcomes
Overall Effectiveness
+50%
Response Rate
+40%
Common Side Effects
Dysgeusia (altered taste)
+25%
Diarrhea
+12%
Nausea
+8%

Sources:

yale.edu
umn.edu
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
3 active trials recruiting for Nirmatrelvir/Ritonavir (Paxlovid) in Long Covid

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

NCT06792214RECRUITINGPHASE4
View Study
118 participants
INTERVENTIONAL
Kingston, Canada +3 more
Started: Jan 3, 2025

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

NCT05852873ACTIVE NOT RECRUITINGPHASE3
View Study
2K participants
INTERVENTIONAL
Bergen, Norway
Started: May 12, 2023

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

NCT06441955RECRUITINGPHASE4
View Study
100 participants
INTERVENTIONAL
Bethesda, United States
Started: Mar 1, 2024
Completed Clinical Trials
6 completed trials for Nirmatrelvir/Ritonavir (Paxlovid) in Long Covid

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

NCT05668091COMPLETEDPHASE2
View Study
100 participants
INTERVENTIONAL
New Haven, United States
Started: Apr 14, 2023

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms

NCT05965726COMPLETEDPHASE2
View Study
964 participants
INTERVENTIONAL
Durham, United States
Started: Jul 26, 2023

Paxlovid for Treatment of Long Covid

NCT05576662COMPLETEDPHASE2
View Study
168 participants
INTERVENTIONAL
Stanford, United States
Started: Nov 8, 2022

ImPROving Quality of LIFe in the Long COVID Patient

NCT05823896COMPLETEDPHASE2
View Study
219 participants
INTERVENTIONAL
Stockholm, Sweden
Started: May 1, 2023

RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

NCT05595369COMPLETEDPHASE2
View Study
963 participants
INTERVENTIONAL
Birmingham, United States +68 more
Started: Jul 26, 2023

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

NCT07090486COMPLETED
View Study
14K participants
OBSERVATIONAL
New York, United States
Started: Apr 15, 2025